Nektar Therapeutics (NKTR) Receivables - Other (2018 - 2025)

Nektar Therapeutics' Receivables - Other history runs 8 years deep, the most recent figure standing at $600000.0 for Q4 2025.

• In Q4 2025, Receivables - Other fell 45.45% year-over-year to $600000.0; the TTM figure through Dec 2025 stood at $600000.0 (down 45.45% YoY), while the FY2025 annual figure was $600000.0, down 45.45% from the prior year.
• Receivables - Other was $600000.0 for Q4 2025 at Nektar Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.4 million in Q4 2021 to a low of $500000.0 in Q4 2023.
• Historically, Receivables - Other has averaged $860000.0 across 5 years, with a median of $700000.0 in 2022.
• The sharpest annual moves came in 2021 and 2024: Receivables - Other tumbled 72.55% in 2021, then soared 120.0% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.4 million in 2021, then tumbled by 50.0% to $700000.0 in 2022, then decreased by 28.57% to $500000.0 in 2023, then surged by 120.0% to $1.1 million in 2024, then slumped by 45.45% to $600000.0 in 2025.
• The last three Receivables - Other figures came in at $600000.0 (Q4 2025), $1.1 million (Q4 2024), and $500000.0 (Q4 2023), per Business Quant data.